TP53 and Miyoshi myopathy: Additionally, treatment of MM TP53-WT cell lines with Nutlin, which interferes with MDM2-p53 interaction, releases p53 from negative control and thereby enhances cytotoxicity of bortezomib (Saha et al., 2010).